Pancreatic Cancer: Can the “King of Cancers” Be Overcome? A Shanghai Treatment Guide

Pancreatic cancer is often called the “king of cancers” because it is difficult to detect early, progresses quickly, and is frequently diagnosed after surgery is no longer straightforward. Yet the label can hide an important truth: pancreatic cancer is not untreatable. Earlier diagnosis, expert surgical assessment, stronger chemotherapy, minimally invasive technology, precision medicine, nutrition, and multidisciplinary planning are expanding the options available to selected patients.

The most useful question is not whether pancreatic cancer has been “defeated” in general. It is whether this individual patient has been staged accurately, reviewed by an experienced pancreatic team, and offered the right sequence of treatment without losing time or physical strength.

Why Survival Has Remained Low

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer and one of the most aggressive solid tumors. Long-term survival has remained low for several connected reasons:

• Early tumors often cause no specific symptoms;
• The pancreas lies deep in the abdomen and cannot be examined directly;
• The disease may spread microscopically before it becomes visible on routine imaging;
• Only a minority of patients have clearly resectable disease at diagnosis;
• The tumor microenvironment can limit treatment response;
• Obstructive jaundice, pain, diabetes, digestive problems, and weight loss can reduce treatment tolerance;
• Recurrence can occur even after a technically successful operation.

Population statistics describe groups, not an individual future. Outcome varies according to stage, tumor biology, resectability, treatment response, surgical quality, general health, and access to coordinated care.

For an overview of staging and treatment, read our pancreatic cancer guide for international patients in Shanghai.

The Anatomical Challenge: Deep Location, Major Blood Vessels, Late Detection

The pancreas lies behind the stomach, close to the duodenum, bile duct, portal vein, superior mesenteric vessels, spleen, and other critical structures. A tumor in the pancreatic head can obstruct the bile duct and cause jaundice. A tumor in the body or tail may remain silent until it becomes larger or spreads.

Possible warning signs include painless jaundice, dark urine, pale stool, persistent upper abdominal or back pain, unexplained weight loss, poor appetite, new or suddenly worsening diabetes, pancreatitis without a clear cause, or unexplained blood clots. These symptoms have many possible causes, but they require medical assessment.

Diagnosis and staging may involve a pancreas-protocol multiphase CT, MRI or MRCP, endoscopic ultrasound with biopsy, laboratory tests including CA 19-9, and sometimes PET-CT or staging laparoscopy. CA 19-9 cannot diagnose or exclude pancreatic cancer by itself and may be affected by jaundice or inflammation.

Who Should Be Screened?

Routine screening is not recommended for the general population because no simple blood test or scan has proved effective enough for everyone. Surveillance may be considered for people with a strong family history, certain inherited cancer syndromes, or defined pancreatic cysts and precursor lesions.

High-risk surveillance should be performed in an experienced program using individualized MRI/MRCP, endoscopic ultrasound, or other testing. New-onset diabetes alone does not mean pancreatic cancer, but sudden diabetes with weight loss or other concerning features deserves careful review.

Learn more in our pancreatic cancer risk and screening guide.

Resectability Is the First Major Decision

Pancreatic cancer is commonly classified as resectable, borderline resectable, locally advanced, or metastatic. This classification depends on distant spread and the tumor’s relationship to major arteries and veins, not simply its diameter.

A high-quality pancreas-protocol CT should be reviewed by radiologists and surgeons experienced in pancreatic cancer. A patient considered inoperable at one center may occasionally be reassessed differently after specialist imaging review or a strong response to treatment. However, surgery should not be promised when safe complete removal is unlikely.

Key questions include:

• Is there disease outside the pancreas?
• Does the tumor involve the superior mesenteric artery, celiac axis, portal vein, or superior mesenteric vein?
• Could involved veins be reconstructed safely?
• Is treatment needed before surgery?
• Is the patient physically and nutritionally ready for a major operation?

Surgical Breakthroughs: Robotic Pancreatic Surgery at Ruijin Hospital

Surgery remains the main potentially curative treatment for localized pancreatic cancer. Depending on tumor location, the operation may be a pancreaticoduodenectomy, also called a Whipple procedure, a distal pancreatectomy, or, less commonly, a total pancreatectomy.

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, has developed a major pancreatic surgery program under Prof. Shen Baiyong. The team has advanced minimally invasive and robotic approaches for selected pancreatic operations and built care pathways around surgery, anesthesia, imaging, oncology, critical care, nutrition, and rehabilitation.

Robotic surgery can provide magnified three-dimensional vision, stable instrument control, and precise movement in deep anatomical spaces. It may reduce incision-related trauma for suitable patients, but it does not make pancreatic surgery minor or risk-free. Tumor biology, vascular involvement, previous surgery, inflammation, body composition, and surgeon experience all affect whether an open, laparoscopic, or robotic approach is safest.

Potential complications include pancreatic fistula, delayed stomach emptying, bleeding, infection, bile leakage, diabetes, digestive enzyme insufficiency, and nutritional decline. Patients should choose a center for its complete pancreatic care system, not for a machine alone.

Explore Prof. Shen Baiyong’s clinical profile and our feature on pancreatic cancer surgery and full life-cycle care at Ruijin Hospital.

Systemic Treatment: Creating More Opportunities for Surgery

Pancreatic cancer is treated as both a local and systemic disease. Chemotherapy may be used before surgery, after surgery, or as the principal treatment for locally advanced or metastatic disease.

For resectable disease, some patients proceed directly to surgery followed by adjuvant chemotherapy, while others may receive treatment first because of high-risk features. For borderline resectable disease, preoperative chemotherapy, sometimes combined with radiotherapy, can treat microscopic disease early and help identify tumors with more favorable biology.

Common multi-drug regimens may include modified FOLFIRINOX or gemcitabine-based combinations, but selection depends on performance status, age, liver and kidney function, bilirubin, neuropathy risk, nutrition, and treatment goals. Dose adjustment is not treatment failure; it can be necessary to maintain safe, continuous care.

After several treatment cycles, the multidisciplinary team may repeat imaging and review CA 19-9 trends, symptoms, nutrition, and physical condition. A meaningful response can create an opportunity to reconsider surgery in selected borderline or locally advanced cases. This conversion strategy requires careful surgical judgment and does not guarantee that resection will become possible.

Radiotherapy, Local Treatment, and Clinical Research

Radiotherapy may be considered for selected borderline resectable, locally advanced, recurrent, or symptomatic disease. Modern techniques aim to limit exposure to the stomach, bowel, liver, kidneys, and spinal cord. The best timing and dose depend on previous treatment and anatomy.

Other local approaches may be discussed in highly selected cases or clinical studies, but they should not replace established treatment without a clear multidisciplinary rationale. Patients interested in vaccines, cellular therapies, targeted drugs, or other experimental approaches should ask whether there is a properly designed clinical trial, what phase it is in, and what standard options remain available.

Precision Medicine: Important, but Not a Shortcut

Germline genetic testing is increasingly relevant for patients with pancreatic cancer because inherited variants can affect treatment and family counseling. Tumor molecular profiling may identify uncommon but actionable changes involving DNA repair pathways, microsatellite instability, NTRK fusions, KRAS variants, or other targets.

Most patients will not have a highly actionable result, but testing can still be valuable when recommended by the treating team. A commercial report should be interpreted in the context of pathology, stage, previous therapy, and drug availability.

Why Shanghai Is an Important Destination for Pancreatic Cancer Care

Shanghai offers two major and complementary pancreatic cancer ecosystems.

Ruijin Hospital brings strength in complex pancreatic surgery, minimally invasive and robotic techniques, vascular reconstruction, perioperative care, and full-course management under teams including Prof. Shen Baiyong.

Fudan University Shanghai Cancer Center brings a specialist cancer-hospital model integrating pancreatic surgery, medical oncology, radiotherapy, imaging, pathology, translational research, and clinical trials. Its pancreatic teams, including specialists such as Prof. Xu Jin and Prof. Yu Xianjun, manage complex localized and advanced disease.

Read more about pancreatic cancer treatment at Fudan University Shanghai Cancer Center.

The two-center landscape is valuable because patients may need different expertise at different stages: a second review of resectability, preoperative therapy, complex surgery, postoperative chemotherapy, radiotherapy, recurrence management, or access to clinical research.

Nutrition, Enzymes, Diabetes, and Symptom Control

Pancreatic cancer can impair digestion and metabolism even before treatment. Weight loss, muscle loss, oily or floating stool, bloating, diarrhea, poor appetite, pain, and unstable blood sugar should be addressed early.

Support may include:

• Pancreatic enzyme replacement taken correctly with meals and snacks;
• Energy-dense, high-protein meals in smaller portions;
• Dietitian review before and after surgery;
• Diabetes monitoring and individualized medication or insulin;
• Pain management, including specialist procedures when appropriate;
• Biliary drainage for selected patients with obstructive jaundice;
• Exercise and rehabilitation adapted to treatment tolerance;
• Early palliative and supportive care alongside anticancer treatment.

Supportive care is not giving up. It can improve strength, treatment tolerance, symptom control, and quality of life at every stage.

Questions to Ask the Multidisciplinary Team

• Has the diagnosis been confirmed by pathology?
• Is the disease resectable, borderline resectable, locally advanced, or metastatic?
• Has the pancreas-protocol CT been reviewed by an experienced pancreatic surgeon and radiologist?
• Should treatment begin with surgery or systemic therapy?
• Could vascular resection or reconstruction be required?
• Is robotic surgery appropriate, or would open surgery be safer?
• What is the goal of chemotherapy, and when will resectability be reassessed?
• Are germline testing and tumor profiling indicated?
• How will nutrition, enzymes, diabetes, jaundice, pain, and blood clots be managed?
• Is a second opinion or clinical trial relevant now?

Our guide to choosing a pancreatic cancer specialist in Shanghai can help patients compare teams more meaningfully.

How CMCS Supports International Patients in Shanghai

China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize medical information, identify appropriate specialists in Shanghai, and coordinate care before, during, and after appointments.

Depending on the case, CMCS can assist with:

• Organizing pancreas-protocol CT or MRI, pathology, endoscopic ultrasound, CA 19-9 trends, genetic results, and previous treatment records;
• Coordinating evaluation by pancreatic surgery, medical oncology, radiation oncology, gastroenterology, genetics, nutrition, or a multidisciplinary team;
• Preparing a concise bilingual case summary and prioritized consultation questions;
• Supporting appointment planning, travel preparation, on-site communication, and examination scheduling;
• Helping patients track chemotherapy, surgery, nutrition, enzyme use, diabetes, and follow-up milestones;
• Facilitating necessary communication with family members after receiving the patient’s authorization.

Remote record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent medical records before case coordination. CMCS can usually address approximately three to five core questions during initial screening. If specific medical coordination is required, the service scope and applicable fee will be explained in advance.

Conclusion: Realistic About Prognosis, Serious About Every Opportunity

Pancreatic cancer remains one of the hardest solid tumors to treat. Honest care does not minimize that reality, but it also does not assume that every patient has the same outcome. Accurate staging, specialist review, timely systemic therapy, expert surgery when appropriate, and strong nutritional and symptom support can materially change the treatment path.

There is no shortcut or guaranteed cure. The best available route is standardized, multidisciplinary treatment delivered without avoidable delay, with resectability and treatment goals reassessed as new information emerges.

Contact CMCS

For help organizing pancreatic cancer records, connecting with appropriate specialists in Shanghai, or planning a medical visit, contact us:

• Website: www.medicalsh.com
• Email: contract@medicalsh.com
• WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1

You may also submit your information through our contact page.

Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment advice. Imaging, biopsy, chemotherapy, surgery, radiotherapy, genetic testing, nutrition, and follow-up plans must be determined by qualified physicians using the patient’s complete medical information.